Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

468
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
468
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

806
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
806
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

899
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
899
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

917
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
917

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conserved T cell receptor usage underpins recognition of CD1c presenting a mycobacterial lipid.

bioRxiv : the preprint server for biology·2026
Same author

Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.

The Lancet. Microbe·2026
Same author

BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis.

Cell reports. Medicine·2026
Same author

IFN-γ- GranzymeB + Natural killer cells are induced by IV BCG vaccination and associated with protection against tuberculosis in rhesus macaques.

Mucosal immunology·2025
Same author

Infant CD4 T-Cell Response to SARS-CoV-2 mRNA Vaccination Is Restricted in Cytokine Production and Modified by Vaccine Manufacturer.

Open forum infectious diseases·2025
Same author

Infant CD4 T-cell response to SARS-CoV-2 mRNA vaccination is restricted in cytokine production and modified by vaccine manufacturer.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K

A systematic approach to tuberculosis vaccine development.

Chetan Seshadri1

  • 1Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA.

Cell
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

A new trivalent mRNA vaccine shows promise against tuberculosis (TB), a leading infectious killer. This novel vaccine provides durable protection in mice and boosts the effectiveness of the existing BCG vaccine.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.5K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.5K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a major global health threat, causing significant mortality worldwide.
  • The current Bacillus Calmette-Guérin (BCG) vaccine offers variable protection against TB.
  • There is an urgent need for more effective TB vaccines.

Purpose of the Study:

  • To identify novel antigens for an improved tuberculosis vaccine.
  • To develop and evaluate a new trivalent mRNA vaccine against TB.
  • To assess the vaccine's efficacy alone and in combination with BCG.

Main Methods:

  • Systematic evaluation of 42 candidate antigens for Mycobacterium tuberculosis.
  • Development of a trivalent mRNA vaccine formulation.
  • Testing vaccine efficacy in multiple mouse models of tuberculosis.
  • Assessment of protection conferred by the mRNA vaccine and its synergy with BCG.

Main Results:

  • The developed trivalent mRNA vaccine demonstrated effective and durable protection against tuberculosis in mouse models.
  • The mRNA vaccine significantly enhanced the protective immunity provided by the BCG vaccine.
  • Specific antigens were identified and validated for their role in protective immunity.

Conclusions:

  • A novel trivalent mRNA vaccine represents a promising strategy for tuberculosis prevention.
  • Combination therapy with the new mRNA vaccine and BCG may offer superior protection.
  • Further development of this mRNA vaccine holds potential for controlling the global tuberculosis epidemic.